Stay updated with breaking news from Intercept Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Primary Biliary Cholangitis is a rare, progressive, chronic autoimmune disease of the liver in which the small bile ducts are gradually destroyed, causing bile and other toxins to build up in the liver (known as cholestasis).
Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a type of fatty liver disease called nonalcoholic... | June 5, 2023
A panel of advisers to the U.S. Food and Drug Administration voted against approving Intercept Pharmaceuticals' (ICPT) investigational treatment for Nonalcoholic steatohepatitis, a serious progressive liver disease.
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Intercept Pharma (ICPT – Research Report), wi...
RBC Capital analyst Brian Abrahams maintained a Hold rating on Intercept Pharma (ICPT – Research Report) on January 13 and set a price tar...